These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7368173)

  • 21. Prevention of venous thrombosis after total knee arthroplasty. Comparison of antithrombin III and low-dose heparin with dextran.
    Francis CW; Pellegrini VD; Stulberg BN; Miller ML; Totterman S; Marder VJ
    J Bone Joint Surg Am; 1990 Aug; 72(7):976-82. PubMed ID: 1696577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis.
    Holst J; Lindblad B; Wedeberg E; Bergqvist D; Nordfang O; Ostergaard PB; Hedner U
    Thromb Res; 1993 Dec; 72(5):467-70. PubMed ID: 8303690
    [No Abstract]   [Full Text] [Related]  

  • 23. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery.
    Zaidan JR; Johnson S; Brynes R; Monroe S; Guffin AV
    Anesth Analg; 1986 Apr; 65(4):377-80. PubMed ID: 3954111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulation by constant subcutaneous heparin infusion.
    Parrilla N; Ansell J
    Thromb Haemost; 1982 Feb; 47(1):1-2. PubMed ID: 7071800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report.
    Cirisano FD; Lee S; Greenspoon JS
    J Reprod Med; 1996 Mar; 41(3):191-4. PubMed ID: 8778420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Continuous heparin therapy in deep venous thrombosis and its monitoring with the Howel and thrombin times. Prospective study].
    Lozano Sánchez F; Almazán Enríquez A; Ramos Boyero M; del Villar Galán JL; Gómez Alonso A
    Angiologia; 1981; 33(5):272-82. PubMed ID: 7325396
    [No Abstract]   [Full Text] [Related]  

  • 27. Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma.
    Dahlman TC; Hellgren MS; Blombäck M
    Am J Obstet Gynecol; 1989 Aug; 161(2):420-5. PubMed ID: 2764060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antithrombin III activity in relation to multiple administration of various doses of heparin to normal animals].
    Kudriashov BA; Pastorova VE; Liapina LA
    Vopr Med Khim; 1985; 31(3):37-41. PubMed ID: 4024529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis.
    Prandoni P; Bagatella P; Bernardi E; Girolami B; Rossi L; Scarano L; Marchiori A; Piccioli A; Girolami A
    Ann Intern Med; 1998 Aug; 129(4):299-302. PubMed ID: 9729183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of fluorogenic substrates for the assay of antithrombin III and heparin.
    Bishop RC; Hudson PM; Mitchell GA; Pochron SP
    Ann N Y Acad Sci; 1981; 370():720-30. PubMed ID: 6943977
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis.
    Harenberg J; Huck K; Bratsch H; Stehle G; Dempfle CE; Mall K; Blauth M; Usadel KH; Heene DL
    Haemostasis; 1990; 20 Suppl 1():205-19. PubMed ID: 1964663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heparin 1986. Indications and effective use.
    Ockelford P
    Drugs; 1986 Jan; 31(1):81-92. PubMed ID: 3510115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
    Hull R; Delmore T; Carter C; Hirsh J; Genton E; Gent M; Turpie G; McLaughlin D
    N Engl J Med; 1982 Jan; 306(4):189-94. PubMed ID: 7033782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug therapy of deep venous thrombosis].
    Bounameaux H
    Ther Umsch; 1996 Apr; 53(4):272-6. PubMed ID: 8658349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?
    Brister SJ; Ofosu FA; Buchanan MR
    Thromb Haemost; 1993 Aug; 70(2):259-62. PubMed ID: 8236131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of F1+2 (thrombin) generation in patients with DVT requires increased doses of heparin.
    Korte W; Schmid L
    Blood Coagul Fibrinolysis; 1995 Oct; 6(7):684-6. PubMed ID: 8562843
    [No Abstract]   [Full Text] [Related]  

  • 37. Antithrombin III prophylaxis of venous thromboembolic disease after total hip or total knee replacement.
    Francis CW; Pellegrini VD; Harris CM; Marder VJ
    Am J Med; 1989 Sep; 87(3B):61S-66S. PubMed ID: 2478015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protection against venous thrombosis in an antithrombin-III deficient patient suffering from episodes of arterial thrombosis requiring major surgery. Effects of oral stanozolol in combination with subcutaneous heparin and intravenous AT-III.
    Jespersen J; Gram J; Kluft C; Astrup T
    Am J Clin Pathol; 1985 Jun; 83(6):768-71. PubMed ID: 4003344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experience with a thrombin clotting time assay for measuring heparin activity.
    Penner JA
    Am J Clin Pathol; 1974 May; 61(5):645-53. PubMed ID: 4827049
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits.
    Tazawa S; Ichikawa K; Misawa K; Fukuyama J; Hamano S; Miyata H; Sakuragawa N
    Thromb Res; 1995 Dec; 80(5):391-8. PubMed ID: 8588200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.